Halozyme Secures European Patent For Enhanze Drug Delivery Platform

Halozyme Therapeutics, Inc, a biopharmaceutical firm, recently made the announcement that it had been granted European Patent No. 4269578. This patent covers the Enhanze rHuPH20 product that is made using Halozyme's Enhanze manufacturing methods and is provided to licensees both now and in the future. All the new patent is authorized under Halozyme's Enhanze licenses. It will be valid in 37 European nations until March 6, 2029. 

"This new European patent for Enhanze further strengthens our robust patent estate and extends the durability of our portfolio," said Dr. Helen Torley, president and chief executive officer of Halozyme. "We are pleased to be able to maintain the original royalty rate for Darzalex SC in Europe through March 2029 based on this new patent."

The newly granted patent prevents the royalty rate on sales of Darzalex SC in the European nations where it is validated from being reduced until the patent expires, as stipulated in Halozyme's Enhanze license with Janssen. The current royalty rates for these licenses are already anticipated to extend beyond the expiration of the new patent, so the new patent is not expected to affect royalties under any other Enhanze licenses with an issued or pending collaboration patent.

Halozyme is a biopharmaceutical company working on disruptive solutions to enhance patient experiences and outcomes for both new and established therapies.